Because tumor-infiltrating Tregs restrict the tumor-killing functions of CD8+ T cells in tumor microenvironment, combining selective downregulation of m6A levels in Tregs with tumor immunotherapy may be an effective new therapeutic strategy. The gene discussed is CD8A; the disease is neoplasm.